Das AK, Saboo B, Chawla R, Aravind SR, Rajput R, Singh AK, et al. Time to reposition sulfonylureas in type 2 diabetes management in Indian context: A pragmatic practical approach. Int J Diabetes Dev Ctries. Published online 2023. https://doi.org/10.1007/s13410-023-01192-6

Kalra S, Bahendeka S, Sahay R, Ghosh S, Md F, Orabi A, et al. Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus - International Task Force. Indian J Endocrinol Metab. 2018;22(1):132–57. https://doi.org/10.4103/ijem.IJEM_556_17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kalra S, Aamir AH, Raza A, Das AK, Azad Khan AK, Shrestha D, et al. Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement. Indian J Endocrinol Metab. 2015;19(5):577–96. https://doi.org/10.4103/2230-8210.163171.

Article  CAS  PubMed  PubMed Central  Google Scholar 

WHO[Internet].Diabetes.; 2023.Available from: https://www.who.int/news-room/fact-sheets/detail/diabetes

Inukai K, Watanabe M, Nakashima Y. Efficacy of glimepiride in Japanese type 2 diabetic subjects. Diabetes Res Clin Pract. 2005;68(3):250–7.

CAS  PubMed  Google Scholar 

Rados DV, Pinto LC, Remonti LR. The association between sulfonylurea use and all-cause and cardiovascular mortality: A meta-analysis with trial sequential analysis of randomized clinical trials. PLoS Med. 2016;3:43–51.

Google Scholar 

Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: The Carolina randomized clinical trial. JAMA – J Am Med Assoc. 2019;322(12):1155–66. https://doi.org/10.1001/jama.2019.13772.

Article  CAS  Google Scholar 

GRADE Study Research Group; Nathan DM, Lachin JM, Balasubramanyam A, Burch HB, Buse JB, Butera NM, et al. Glycemia reduction in type 2 diabetes - Glycemic outcomes. N Engl J Med. 2022;387(12):1063–1074. https://doi.org/10.1056/NEJMoa2200433.

Vaccaro O, Masulli M, Nicolucci A, Bonora E, Prato SD, Maggioni AP, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017;5:887–97.

PubMed  Google Scholar 

Wang H, Cordiner RLM, Huang Y, Donnelly L, Hapca S, Collier A, et al. Cardiovascular safety in type 2 diabetes with sulfonylureas as second-line drugs: A nationwide population-based comparative safety study. Diabetes Care. 2023;46(5):967–77. https://doi.org/10.2337/dc22-1238.

Article  CAS  PubMed  PubMed Central  Google Scholar 

He W, Yuan G, Han Y, Yan Y, Li G, Zhao C, et al. Glimepiride use is associated with reduced cardiovascular mortality in patients with type 2 diabetes and chronic heart failure: a prospective cohort study. Eur J Prev Cardiol. 2023;30(6):474–87. https://doi.org/10.1093/eurjpc/zwac312.

Article  Google Scholar 

Volke V, Katus U, Johannson A, Toompere K, Heinla K, Rünkorg K, et al. Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs. BMC Endocr Disord. 2022;22(1). https://doi.org/10.1186/s12902-022-01158-5

Massi-Benedetti M. Glimerpiride in type 2 diabetes mellitus: A review of the worldwide therapeutic experience. Clin Ther. 2003;25(3):799–816. https://doi.org/10.1016/S0149-2918(03)80109-1.

Article  CAS  PubMed  Google Scholar 

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet.1998;352(9131):837–853. https://doi.org/10.1016/S0140-6736(98)07019-6

Heller SR. ADVANCE Collaborative Group. A summary of the ADVANCE Trial. Diabetes Care. 2009;32(2):S357–61. https://doi.org/10.2337/dc09-S339.

Lim LL, Lau ESH, Cheung JTK, Chan SP, Ji L, Lim S, et al. Real-world usage of sulphonylureas in Asian patients with type 2 diabetes using the Joint Asia Diabetes Evaluation (JADE) register. Diabetes Obes Metab. 2023;25(1):208–21. https://doi.org/10.1111/dom.14865.

Article  CAS  PubMed  Google Scholar 

Meshram DM, Langade DG, Kinagi SB, Naikwadi AA, Morye V, Chopra D, et al. Evaluation of efficacy and safety of fixed dose combination of glimepiride 2 mg plus pioglitazone 15 mg plus metformin SR 500 mg in the management of patients with type-2 diabetes mellitus. J Indian Med Assoc. 2005;103:447–50.

CAS  PubMed  Google Scholar 

Nakamura I, Oyama J, Komoda H, Shiraki A, Sakamoto Y, Taguchi I, et al. Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report. Cardiovasc Diabetol. 2014;14(13):15. https://doi.org/10.1186/1475-2840-13-15.

Article  CAS  Google Scholar 

Zekry R, Omran GA, El-Gharbawy NM, Werida RH. Comparative study of Dapagliflozin versus Glimepiride effect on insulin-regulated aminopeptidase (IRAP) and interleukin-34 (IL-34) in patient with type 2 diabetes mellitus. Nature. 2023;13(6302). https://doi.org/10.1038/s41598-023-33417-3

Wong L, Chen HM, Lai SQ, Yang HZ, Kuang J, Pei JH. Effects of sulfonylurea as initial treatment on testosterone of middle-aged men with type 2 diabetes: A 16-week, pilot study. J Diabetes Investig. 2015;6(4):454–9. https://doi.org/10.1111/jdi.12324.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nguyen C, Pan J, Charles MA. Preclinical studies of glimepiride. Drugs Today (Barc). 1998;34(5):391–400. https://doi.org/10.1358/dot.1998.34.5.472189.

Article  CAS  PubMed  Google Scholar 

Hussien NR, Al-Naimi MS, Rasheed HA, Al-kuraishy HM, Al-Gareeb AI. Sulfonylurea and neuroprotection: The bright side of the moon. J Adv Pharmaceut Technol Res. 2018;9(4):120–3. https://doi.org/10.4103/japtr.JAPTR_317_18.

Article  CAS  Google Scholar 

Zhang G, Lin X, Zhang S, Xiu H, Pan C, Cui W. A protective role of glibenclamide in inflammation-associated injury. Mediators Inflamm. 2017;2017:3578702. https://doi.org/10.1155/2017/3578702.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ye JH, Qian MH, Shi LZ, Ye L. Association between metformin and sulfonylurea monotherapies and cancer incidence: A real-world cohort study in Shanghai. China Diabetes Ther. 2019;10(1):245–58. https://doi.org/10.1007/s13300-018-0557-3.

Article  CAS  PubMed  Google Scholar 

Moon JS, Ha KS, Yoon JS, Lee HW, Lee HC, Won KC, et al. The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: Open-label, randomized, controlled study. Acta Diabetol. 2014;51:277–85.

CAS  PubMed  Google Scholar 

Koshiba K, Nomura M, Nakaya Y, Ito S. Efficacy of Glimeriride on insulin resistance, adipocytokines, and atherosclerosis. J Med Invest. 2006;53:87–94.

PubMed  Google Scholar 

Kalra S, Das AK, Baruah MP, Unnikrishnan AG, Dasgupta A, Shah P, et al. Glucocrinology of modern sulfonylureas: Clinical evidence and practice-based opinion from an international expert group. Diabetes Ther. 2019;10(5):1577–93. https://doi.org/10.1007/s13300-019-0651-1.

Article  PubMed  PubMed Central  Google Scholar 

Shrivastava A, Kesavadev J, Mohan V, Saboo B, Shrestha D, Maheshwari A. et al. Clinical evidence and practice-based guidelines on the utility of basal insulin combined oral therapy (Metformin and Glimepiride) in the current era. Current Diabetes Reviews. 2023;19(8). https://doi.org/10.2174/1573399819666230109104300

Hirst JA, Farmer AJ, Dyar A, Lung TWC, Stevens RJ. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia. 2013;56:973–84. https://doi.org/10.1007/s00125-013-2856-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim HS, Kim DM, Cha BS, Park TS, Kim KA, Kim DL, et al. Efficacy of glimepiride/metformin fixed-dose combination vs. metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea. J Diabetes Investig. 2014;5:701–8.

CAS  PubMed  PubMed Central  Google Scholar 

Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med. 2001;18:828–34.

CAS  PubMed  Google Scholar 

González-Ortiz M, Martínez-Abundis E. Grupo para el Tratamiento de la Diabetes Mellitus con Combinaciones. Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy Rev Invest Clin. 2004;56:327–33

Bolen S, Tseng E, Hutfless S, Segal JB, Suarez-Cuervo C, Berger Z, et al. Diabetes medications for adults with type 2 diabetes: An update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016(Comparative Effectiveness Reviews, No. 173.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK362863/

Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr Med Res Opin. 2006;22:751–9. https://doi.org/10.1185/030079906X104786.

Article  CAS  PubMed  Google Scholar 

Amate J, Lopez-Cuadrado T, Almendro N, Bouza C, Saz-Parkinson Z, Rivas-Ruiz R, et al. Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: Systematic review and meta-analysis. Int J Clin Pract. 2015;69(3):292–304. https://doi.org/10.1111/ijcp.12605.

Article  CAS  PubMed  Google Scholar 

Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC; EMPA-REG H2H-SU trial investigators. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014 Sep;2(9):691–700. https://doi.org/10.1016/S2213-8587(14)70120-2. Epub 2014 Jun 16. Erratum in: Lancet Diabetes Endocrinol. 2015 Sept;3(9):e7.

Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial Diabetes Care. 2011;34:2015–22

Nauck M, Frid A, Hermansen K, Thomsen AB, During M, Shah N, et al. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab. 2013;15:204–12. https://doi.org/10.1111/dom.12012.

Article  CAS